IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v19y2001i5p497-512.html
   My bibliography  Save this article

Cost Effectiveness of Ramipril in Patients with Non-Diabetic Nephropathy and Hypertension

Author

Listed:
  • Peter Schädlich
  • Josef Brecht
  • Massimo Brunetti
  • Eva Pagano
  • Badrudin Rangoonwala
  • Eduard Huppertz

Abstract

Background: In the Ramipril Efficacy In Nephropathy (REIN) trial, ramipril significantly lowered the rate of reaching the combined end-point of doubling of baseline serum creatinine levels or end-stage renal failure (ESRF). Objective: To determine the additional cost per patient-year of chronic (long term) dialysis avoided (PYCDA) when the ACE inhibitor, ramipril, was added to conventional treatment of patients with non-diabetic nephropathy and hypertension. Study perspective: Statutory Health Insurance (SHI) provider in Germany. Design and setting: Data from the REIN Study were used in a cost-effectiveness analysis (CEA). A modelling approach was used, which was based on secondary analysis of published data, and costs were those incurred by the SHI provider (i.e. SHI expenses). In the base-case analysis, average case-related SHI expenses were applied and PYCDA were quantified using the cumulative incidence of ESRF as observed in the REIN trial. Main outcome measures and results: The incremental cost-effectiveness ratios (ICERs) of ramipril varied between about − 76 700 deutschmarks (DM) and -DM81 900 per PYCDA(DM1 ≈ 0.55 US dollars; 1999 values), according to the treatment periods of 1 year and 3 years, respectively. In the sensitivity analysis, the robustness of the model and its results were shown when the extent of influence of different model variables on the base-case results was investigated. First, probabilities of ESRF and PYCDA were estimated according to the Weibull method. Second, the influence of the model variables on the target variable was quantified using a deterministic model. Third, the dependency of the target variable (ICER) on random variables was described in a simulation. The cost for chronic dialysis had by far the greatest impact on the target variable, which was 28 times greater than the impact of clinical effectiveness of ramipril, i.e. the number of PYCDA. There were net savings per PYCDA with ramipril treatment after 1, 2 and 3 years: 95% of the 10 000 simulation steps resulted in savings of between DM69 500 and DM94 600 per PYCDA after 3 years. Conclusions: Results from this evaluation show that ramipril offers enormous savings from the perspective of the SHI provider (third-party payer) in Germany when added to the conventional treatment of patients with non-diabetic nephropathy and hypertension. Copyright Adis International Limited 2001

Suggested Citation

  • Peter Schädlich & Josef Brecht & Massimo Brunetti & Eva Pagano & Badrudin Rangoonwala & Eduard Huppertz, 2001. "Cost Effectiveness of Ramipril in Patients with Non-Diabetic Nephropathy and Hypertension," PharmacoEconomics, Springer, vol. 19(5), pages 497-512, May.
    • Handle: RePEc:spr:pharme:v:19:y:2001:i:5:p:497-512
    DOI: 10.2165/00019053-200119050-00005
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.2165/00019053-200119050-00005
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.2165/00019053-200119050-00005?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Peter Schädlich & Eduard Huppertz & Josef Brecht, 1998. "Cost-Effectiveness Analysis of Ramipril in Heart Failure after Myocardial Infarction," PharmacoEconomics, Springer, vol. 14(6), pages 653-669, December.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Peter Schädlich & Michael Kentsch & Manfred Weber & Wolfgang Kämmerer & Josef Brecht & Vijay Nadipelli & Eduard Huppertz, 2006. "Cost Effectiveness of Enoxaparin as Prophylaxis against Venous Thromboembolic Complications in Acutely Ill Medical Inpatients," PharmacoEconomics, Springer, vol. 24(6), pages 571-591, June.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:19:y:2001:i:5:p:497-512. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.